

## Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following was observed with cemiplimab as neoadjuvant therapy for Stage II to IV cutaneous squamous cell carcinoma?**
  - A complete or major pathological response in 90% of patients
  - A complete or major pathological response in 64% of patients**
  - A complete or major pathological response in 18% of patients
- 2. The Phase III DREAMseq trial evaluating the optimal treatment sequence of combination dabrafenib/trametinib and combination nivolumab/ipilimumab for patients with treatment-naïve BRAF-mutant metastatic melanoma demonstrated which of the following outcomes?**
  - The sequence beginning with nivolumab/ipilimumab resulted in a 20% absolute improvement in 2-year overall survival compared to beginning with dabrafenib/trametinib**
  - The sequence beginning with dabrafenib/trametinib resulted in a 20% absolute improvement in 2-year overall survival compared to beginning with nivolumab/ipilimumab
  - There was no difference in overall survival between the two treatment sequences
- 3. Which of the following best describes the mechanism of action of fianlimab?**
  - Anti-PD-1 antibody
  - Hedgehog inhibitor
  - Anti-LAG3 antibody**
- 4. What was the approximate objective response rate (ORR) observed with the combination of first-line cemiplimab and fianlimab in patients with advanced melanoma who previously received neoadjuvant anti-PD-1 therapy?**
  - An ORR of 56%**
  - An ORR of 56%
  - An ORR of 25%
  - An ORR of 25%
- 5. The ongoing Phase III TILVANCE-301 trial is evaluating which novel agent in combination with pembrolizumab versus pembrolizumab alone in patients with untreated unresectable or metastatic melanoma?**
  - Fianlimab
  - Cemiplimab
  - Lifileucel**